ProNAi Therapeutics is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with cancer. We are an ambitious oncology focused company, oriented towards achieving the successful registration and commercialization of our drug candidates. We have a world-class management team with a proven track record of success in oncology drug development and we are building a broad and diverse pipeline of promising assets against emerging targets on the leading edge of cancer biology.
Our lead drug candidate, PNT737, is a highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). Chk1 is a central regulator of the DNA Damage Response (DDR) network, a system of cellular pathways that monitor, signal and repair DNA damage. Cancer cells rely on the DDR network to survive and replicate, despite often possessing high levels of intrinsic genomic instability. Moreover, DNA damage induced by chemotherapies or radiation activates the DDR network in cancer cells, potentially limiting the efficacy of these treatment modalities.
Given the important role of Chk1 in facilitating tumor cell resistance to chemotherapy or radiation-induced DNA damage, the combination of PNT737 with these standards-of-care is anticipated to provide synergistic anti-tumor activity, consistent with findings in preclinical oncology models. PNT737 also has potential utility when administered as monotherapy for the treatment of a range of tumor indications that harbor high degrees of intrinsic DNA damage. Importantly, the oral bioavailability of our drug candidate affords greater dosing flexibility for both monotherapy and combination therapy settings than is possible with intravenously administered agents. PNT737 is currently being investigated in two Phase 1 clinical trials in patients with advanced cancer.
ProNAi is also advancing PNT141, a highly selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). Cdc7 is a key regulator of both DNA replication and the DDR network, making it a compelling emerging target for the potential treatment of a broad range of tumor types. PNT141 is currently undergoing preclinical development with an IND filing anticipated in the second half of 2017.
ProNAi retains the global commercialization rights to both PNT737 and PNT141.